DHODH and leukemia: Studies have shown that the DHODH inhibitors are highly effective in in-vitro, in-vivo pre-clinical leukemia models and currently the clinical efficacy testing of recently developed DHODH inhibitors, BAY2402234 (NCT03404726), and ASLAN003 (NCT03451084) is underway.